循環器ジャーナル70巻2号

2022年04月発行

特集 循環器薬の使い方—使い分け，モニタリング，導入・中止のタイミング Ⅱ章　心不全

RAS阻害薬からARNIまで

著者： 小林雄太¹ 安斉俊久¹

所属機関： ¹北海道大学大学院医学研究院循環病態内科学

ページ範囲：P.218 - P.224

Point
・心不全患者においてACE阻害薬は予後を改善させると報告されている．
・ARBはACE阻害薬に対する優位性は証明されておらず，ACE阻害薬の忍容性がない場合に処方を検討する．
・ARNIはACE阻害薬と比較して優位性を示し，現在急速に普及している薬剤である．
・RAS阻害薬導入にあたっては，低血圧による臓器灌流障害，腎機能障害，電解質異常などに注意する．

参考文献

1）CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study（CONSENSUS）. N Engl J Med 316 : 1429-1435, 1987

2）SOLVD Investigators ; Yusuf S, Pitt B, Davis CE, et al : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 : 293-302, 1991

3）SOLVD Investigators ; Yusuf S, Pitt B, Davis CE, et al : Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 : 685-691, 1992

4）Blood Pressure Lowering Treatment Trialists' Collaboration ; Turnbull F, Neal B, Pfeffer M, et al : Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 25 : 951-958, 2007

5）Lang CC, Struthers AD : Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol 10 : 125-134, 2013

6）Granger CB, McMurray JJ, Yusuf S, et al : Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors : the CHARM-Alternative trial. Lancet 362 : 772-776, 2003

7）Pitt B, Poole-Wilson PA, Segal R, et al : Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure : randomised trial--the Losartan Heart Failure Survival Study ELITE Ⅱ. Lancet 355 : 1582-1587, 2000

8）Dickstein K, Kjekshus J ; OPTIMAAL Steering Committee of the OPTIMAAL Study Group : Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction : the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin Ⅱ Antagonist Losartan. Lancet 360 : 752-760, 2002

9）ONTARGET Investigators ; Yusuf S, Teo KK, Pogue J, et al : Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 : 1547-1559, 2008

10）Savarese G, Costanzo P, Cleland JG, et al : A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 61 : 131-142, 2013

11）Packer M, Poole-Wilson PA, Armstrong PW, et al : Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100 : 2312-2318, 1999

12）van de Ven PJ, Beutler JJ, Kaatee R, et al : Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int 53 : 986-993, 1998

13）Testani JM, Kimmel SE, Dries DL, et al : Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 4 : 685-691, 2011

14）McMurray JJ, Packer M, Desai AS, et al : Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 : 993-1004, 2014

15）Solomon SD, McMurray JJV, Anand IS, et al : Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 381 : 1609-1620, 2019

16）Solomon SD, Vaduganathan M, Claggett BL, et al : Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation 141 : 352-361, 2020

17）Velazquez EJ, Morrow DA, DeVore AD, et al : Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med 380 : 539-548, 2019

18）Wachter R, Senni M, Belohlavek J, et al : Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge : primary results of the randomised TRANSITION study. Eur J Heart Fail 21 : 998-1007, 2019

19）Mann DL, Givertz MM, Vader JM, et al : Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction : A Randomized Clinical Trial. JAMA Cardiol 7 : 17-25, 2022